Oncoviruses: An overview of oncogenic and oncolytic viruses

Oncolytic Viruses

1Genelux Corporation, San Diego Science Center, San Diego, CA 92019, USA 2Department of Radiation Oncology, Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego, CA 92093, USA 3Department of Biochemistry, University of Wuerzburg, 97074 Wuerzburg, Germany 4Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, 97078 Wuerzburg, Germany 5 I...

Oncolytic Viruses: Therapeutics With an Identity Crisis

Oncolytic viruses (OV) are replicating viral therapeutics for the treatment of cancer and have been in laboratory development for about twenty years. Recently, the FDA approved Imlygic, a herpes virus based therapeutic for the treatment of melanoma and thus OVs have entered a new era where they are a weapon in the armament of the oncologist. OVs are unique therapeutics with multiple mechanisms ...

Oncogenic Viruses

Dengue viruses – an overview

Dengue viruses (DENVs) cause the most common arthropod-borne viral disease in man with 50-100 million infections per year. Because of the lack of a vaccine and antiviral drugs, the sole measure of control is limiting the Aedes mosquito vectors. DENV infection can be asymptomatic or a self-limited, acute febrile disease ranging in severity. The classical form of dengue fever (DF) is characterize...

Designing and building oncolytic viruses

Oncolytic viruses (OVs) are engineered and/or evolved to propagate selectively in cancerous tissues. They have a dual mechanism of action; direct killing of infected cancer cells cross-primes anticancer immunity to boost the killing of uninfected cancer cells. The goal of the field is to develop OVs that are easily manufactured, efficiently delivered to disseminated sites of cancer growth, unde...